Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14507958 | 0.87 | CTSS (0.38) | CTSS | |
| SCHEMBL8284106 | 0.84 | LMNA (0.32) | LMNATP53SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL8284114 | 0.82 | HSD17B10 (0.33) | LMNATP53SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL8284127 | 0.82 | LMNA (0.34) | LMNATP53SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL14507993 | 0.81 | SMN1; SMN2 (0.35) | LMNATP53SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL6062378 | 0.78 | ALDH1A1 (0.42) | LMNATP53SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL8284128 | 0.78 | LMNA (0.33) | LMNATP53SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL14507994 | 0.77 | SMN1; SMN2 (0.34) | LMNATP53SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL8283319 | 0.76 | CTSL (0.35) | LMNATP53SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL14507990 | 0.76 | CTSK (0.40) | LMNATP53SMN1; SMN2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105892-A1 | Amidino compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105892-A1 | Amidino compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105892-A1 | Amidino compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | LMNA 1267/4885TP53 1279/4885SMN1; SMN2 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.